Top

Timothy C. Thompson, Ph.D.

Department of Genitourinary Medical Oncology, Division of Cancer Medicine

Present Title & Affiliation

Primary Appointment

Endowed Chair Joan and Stanford Alexander Distinguished Chair for Prostate Cancer Research, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Director of Prostate Cancer Basic Science Research, Department of Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Joan and Stanford Alexander Distinguished Chair for Prostate Cancer Research, Department of Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1985	University of Colorado, Boulder, Colorado, US, Pharmaceutical Sciences-Pharmacology, Ph.D
1974	Indiana University, Bloomington, Indiana, US, Biological Sciences, BA

Postgraduate Training

1985-1988

Research Fellowship, Imperial Cancer Research Fund, London

Experience & Service

Academic Appointments

Jamail-Abramson Chair in Urologic Research, Baylor College of Medicine, Houston, TX, 2001 - 2007

Professor, Baylor College of Medicine, Houston, TX, 1996 - 2007

Associate Professor, Department of Radiology, Baylor College of Medicine, Houston, TX, 1993 - 1996

Associate Professor, Department of Urology, Cell Biology, Baylor College of Medicine, Houston, TX, 1992 - 1996

Assistant Professor, Department of Cell Biology, Baylor College of Medicine, Houston, TX, 1988 - 1992

Assistant Professor, Department of Urology, Baylor College of Medicine, Houston, TX, 1988 - 1992

Administrative Appointments/Responsibilities

Co-Leader, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center - Genitourinary Program of the Cancer Center Support Grant, Houston, TX, 2012 - Present

Co-Leader, Department of Genitourinary Medical Oncology - Research, Prostate Cancer Moon Shot, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018

Director of Prostate Cancer Basic Science Research, Department of Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present

Member, Baylor College of Medicine, Houston, TX, 2003 - 2007

Leader, Department of Prostate Cancer Program, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, 2003 - 2007

Associate Member, Department of Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, 2002 - 2002

Director, Department of Matsunaga-Conte Prostate Cancer Research Center, Baylor College of Medicine, Houston, TX, 1998 - 2007

Director of Research, Department of Scott Department of Urology, Baylor College of Medicine, Houston, TX, 1992 - 2007

Other Appointments/Responsibilities

Member, The University of Texas MD Anderson Cancer Center Prostate Cancer Research Foundation Committee, Houston, TX, 2011 - Present

Member, Pathology Chair Selection Committee, Baylor College of Medicine, Houston, TX, 2006 - 2007

Consultant, EDICT Project, Houston, TX, 2006 - Present

Board Member, National Gene Vector Laboratories (NGVL) Scientific Review Board, Indianapolis, IN, 2003 - 2007

Member, Faculty Committee on Awards, Baylor College of Medicine, Houston, TX, 2002 - 2007

Member, Inter-Prostate SPORE Biomarkers Committee, Baylor College of Medicine, Houston, TX, 2002 - 2007

Internal Advisor, SPORE in Breast Cancer, Baylor College of Medicine, Houston, TX, 2002 - 2007

Member, AACR Career Development Awards in Cancer Research Committee, Philadelphia, PA, 2001 - 2002

Member, Vision 05 Research Resources Tactical Planning Group, Baylor College of Medicine, Houston, TX, 1999 - 2007

Consultantships, Eli Lilly and Co., Inc, Indianapolis, Indiana, 1996 - 1998

Consultantships, Pfizer, Inc, New York, NY, 1996 - 1996

Member, Academic Programs Cancer Center Subcommittee, Baylor College of Medicine, Houston, TX, 1996 - 2007

Member, American Urological Association Molecular Biological Technology Committee, Linthicum, MD, 1996 - 2000

Consultantships, Urocor, Inc, Baltimore, MD, 1995 - 1996

Consultantships, ONCOR, Inc, Gaithersburg, MD, 1995 - 1995

Member, Board of Scientific Directors, Association for the Cure of Cancer of the Prostate, Houston, TX, 1993 - 2003

Consultantships, IDUN Pharmaceuticals, San Diego, CA, 1993 - 1993

Member, Molecular Medicine Training Program Operating Committee, Baylor College of Medicine, Houston, TX, 1993 - 2007

Member, Prostate Cancer Foundation Scientific Board, Santa Monica, CA, 1992 - Present

Member, Medical Scientist Training Program Operating Committee, Baylor College of Medicine, Houston, TX, 1992 - 1998

Member, Scott Department of Urology Research Committee, Baylor College of Medicine, Houston, TX, 1992 - 2007

Member, (SPORE) For Prostate Cancer, Baylor College of Medicine, Molecular Mechanisms Working Group, Houston, TX, 1991 - 2007

Member, (SPORE) For Prostate Cancer, Baylor College of Medicine Scientific Advisory Committee, Houston, TX, 1991 - 2007

Executive Committee Member, NCI Specialized Program of Research Excellence (SPORE) for Prostate Cancer, Baylor College of Medicine, Houston, TX, 1991 - 2007

Member, Infectious Agents and Hazardous Chemicals Subcommittee, Baylor College of Medicine, Houston, TX, 1991 - 1992

Member, Residency Program Committee, Scott Department of Urology, Baylor College of Medicine, Houston, TX, 1991 - 2007

Member, American Urologic Association/American Foundation for Urologic Disease Research Committee, Houston, TX, 1990 - 1992

Member, Research Committee, Scott Department of Urology, Baylor College of Medicine, Houston, TX, 1990 - 2007

Member, Baylor College of Medicine, Faculty Research and Fellowship Support Committee, Houston, TX, 1989 - 2007

Member, Veterans Administration Medical Center, Basic Science Subcommittee, Houston, TX, 1988 - 1991

Institutional Committee Activities

Member, Urology Chair Search Committee, 2024 - 2024

Member, Genitourinary Medical Oncology Search Committee, 2024 - 2024

Reviewer, Mid-Tenure Review Committee of Dr. Guocan Wang, 2020 - Present

Committee Member, Research Integrity Inquiry Committee, 2019 - 2019

Committee Member, Research Integrity Investigation Committee, 2019 - 2019

Reviewer, Mid-Tenure Review Committee of Dr. Min Sup Song, 2016 - 2016

Organizing Committee, MD Anderson Cancer Center PI3K and Metabolism Workshop, 2012 - 2012

Committee Member, Division of Cancer Medicine Research Awards Program, 2011 - 2012

Committee Member, Division of Cancer Medicine Annual Awards Committee, 2009 - 2009

Co-Chair, Prostate Cancer SPORE Signaling Pathways Working Group, 2007 - Present

Committee Member, Prostate Cancer Research Program - GU Medical Oncology, 2007 - Present

Director, Prostate Cancer Basic Science Research, 2007 - Present

Member, Prostate Cancer SPORE, Experimental Therapeutics Working Group, 2007 - Present

Co-Chair, Inter-Prostate SPORE Biomarkers Oversight Committee, 2007 - Present

Honors & Awards

	Predoctoral Fellowship, University of Colorado
	Member, Rho Chi
	Postdoctoral Fellowship, I.C.R.F
	Lamar Fleming Award, Baylor College of Medicine
	Pfizer Visiting Professor, University of Iowa School of Medicine--Department of Urology
	CaP CURE Research Award
	State of the Art Lecturer, European Society for Urological Oncology and Endocrinology, 10th Congress Berne, Switzerland
	Who's Who in the South and Southwest
	Who's Who in Science and Engineering, 3rd Edition
	Jonsson Cancer Center Distinguished Lecturer, University of California at Los Angeles
	U.S. Patent Recipient in CaP CURE Research Award, Baylor College of Medicine Technologies, Inc
	"Partner's in Courage", Achievement Award in Prostate Cancer for Excellence in Research, American Cancer Society
	Distinguished Lecturer, Dean's Biomedical Research Seminar Series, SUNY Health Sciences Center in Syracuse
	Outstanding Contributions to the Study of Molecular Carcinogenesis, University of Oklahoma Health Sciences Center; Department of Biochemistry and Molecular Biology
	Golfers Against Cancer Award, "Development of RTVP-1 Protein Therapy"
	1st Place Basic Science Abstract, "Development of RTVP-1 Protein Therapy for Prostate Cancer", Baylor College of Medicine, 3rd Annual Cancer Center Symposium
	Annual Paul Jackson Rogers Lectureship, Scott and White Healthcare, Temple, Texas
	Keynote Address, Seventh Annual National Symposium on Prostate Cancer, Clark Atlanta University
	Kitasato Institute Tenured (Visiting) Professorship, Kitasato University, Toyko, Japan
	MD Anderson Division of Cancer Medicine Team Science Award, University of Texas MD Anderson Cancer Center
	Potu N. Rao Award for Excellence in Basic Science, MD Anderson Cancer Center

Professional Memberships

DOD PCRP Integration Panel

Ad Hoc Member, 2018 - 2018

American Urological Association

Member, 2017 - Present

American Society for Gene Therapy

Member, 1993 - Present

European Society for Cancer Immunology and Immunotherapy

Member, 1992 - Present

American Association for Cancer Research

Member, 1992 - Present

American Association for the Advancement of Science

Member, 1991 - Present

American Society for Microbiology

Member, 1990 - Present

Society for Basic Urologic Research

Member, 1989 - Present

Metastasis Research Society

Member, 1989 - Present

Selected Publications

Peer-Reviewed Articles

Gregg JR, Newcomb L, Wu R, Dennison J, Davis JW, Pettaway C, Pisters L, Ward JF, Chapin BF, Chery L, Urkmez A, Fang AM, Higgason N, Troncoso P, Daniel CR, Logothetis C, Thompson TC, Hahn AW, Liu M, Zheng Y, Lin DW, Hanash S, Irajizad E, Fahrmann J. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomark Res 12(1):134, 2024. PMID: 39522029.
Wolfe, AR, Cui, T, Baie, S, Corrales-Guerrero, S, Webb, A, Castro-Aceituno, V, Shyu, DL, Karasinska, JM, Topham, JT, Renouf, DJ, Schaeffer, DF, Halloran, M, Packard, R, Robb, R, Chen, W, Denko, N, Lisanti, M, Thompson, T, Frank, P, Williams, TM. Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Science Advances 10(9), 2024. PMID: 38427741.
Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S, Wu C, Park S, Kondraganti S, Wang D, Robinson BD, Loda M, Barbieri CE, Yap TA, Corn PG, Hanash S, Broom BM, Pilie PG, Thompson TC. SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor-induced growth suppression. Clinical Cancer Research 29(21):4464-4478, 2023. PMID: 37581614.
Linares JF, Cid-Diaz T, Duran A, Osrodek M, Martinez-Ordoñez A, Reina-Campos M, Kuo HH, Elemento O, Martin ML, Cordes T, Thompson TC, Metallo CM, Moscat J, Diaz-Meco MT. The Lactate-NAD+ axis activates cancer associated fibroblasts by downregulating p62. Cell Rep 39(6):110792, 2022. PMID: 35545049.
Geng C, Thompson TC. DNA Damage Response Inhibitor and Anti-PD-L1 Therapy for Prostate Cancer: Development of Predictive Biomarkers. Engineering 12(2095-8099):12-15, 2022. PMID: None.
Wu C, Peng S, Pilie PG, Geng C, Park S, Manyam GC, Lu Y, Yang G, Tang Z, Kondraganti S, Wang D, Hudgens CW, Ledesma DA, Marques-Piubelli ML, Torres Cabala CA, Curry JL, Troncoso P, Corn PG, Broom BM, Thompson TC. PARP and CDK4/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer. Mol Cancer Ther 20(9):1680-1691, 2021. e-Pub 2021. PMID: 34158347.
Tang Z, Pilié PG, Geng C, Manyam GC, Yang G, Park S, Wang D, Peng S, Wu C, Peng G, Yap TA, Corn PG, Broom BM, Thompson TC. ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer. Clin Cancer Res 27(17):4898-4909, 2021. e-Pub 2021. PMID: 34168048.
Yanagisawa N, Satoh T, Tabata KI, Tsumura H, Nasu Y, Watanabe M, Thompson TC, Okayasu I, Murakumo Y, Baba S, Iwamura M. Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer. Asian J Urol 8(3):280-288, 2021. e-Pub 2020. PMID: 34401335.
Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol 79(2):298-306, 2021. e-Pub 2020. PMID: 33279304.
Han Y, Zhang M, Xu J, Li J, Xu Y, Thompson TC, Logothetis CJ, Sun D, Gu J. Genome-wide DNA methylation profiling of leukocytes identifies CpG methylation signatures of aggressive prostate cancer. Am J Cancer Res 11(3):968-978, 2021. e-Pub 2021. PMID: 33791167.
Deng Y, Xie K, Logothetis CJ, Thompson TC, Kim J, Huang M, Chang DW, Gu J, Wu X, Ye Y. Genetic Variants in Epithelial Mesenchymal Transition Genes as Predictors of Clinical Outcomes in Localized Prostate Cancer. Carcinogenesis 41(8):1057-1064, 2020. e-Pub 2020. PMID: 32215555.
Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, Park S, Yang G, Creighton CJ, Fleury A, Mayo J, Paulucci-Holthauzen A, Dennison JB, Murage E, Peterson CB, Davis JW, Kim J, Hanash S, Thompson TC. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun 11(1):4279, 2020. e-Pub 2020. PMID: 32855410.
Vykoukal JV, Fahrmann JF, Thompson TC. Caveolin and lipid domains-close companions in managing cellular pathways. Cancer Metastasis Rev 39(2):341-342, 2020. PMID: 32417992.
Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. e-Pub 2020. PMID: 32359397.
Xu J, Chang WS, Tsai CW, Bau DT, Xu Y, Davis JW, Thompson TC, Logothetis CJ, Gu J. Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine 52:102616, 2020. e-Pub 2020. PMID: 31981976.
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res 25(23):6916-6924, 2019. e-Pub 2019. PMID: 31363002.
Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res 25(22):6839-6851, 2019. e-Pub 2019. PMID: 31439587.
Huang L, Brunell D, Stephan C, Mancuso J, Yu X, He B, Thompson TC, Zinner R, Kim J, Davies P, Wong STC. Driver Network as a Biomarker: Systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction. Bioinformatics 35(19):3709-3717, 2019. e-Pub 2019. PMID: 30768150.
Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 20(10):1432-1443, 2019. e-Pub 2019. PMID: 31515154.
Xu J, Chang WS, Tsai CW, Bau DT, Davis JW, Thompson TC, Logothetis CJ, Gu J. Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans. Carcinogenesis. e-Pub 2019. PMID: 31408512.
Wang Q, Gregg JR, Gu J, Ye Y, Chang DW, Davis JW, Thompson TC, Kim J, Logothetis CJ, Wu X. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. Oncoimmunology 8(1):e1483303, 2019. e-Pub 2018. PMID: 30546938.
Thompson TC, Liu B, Li L. N-MYC regulation of DNA damage response in neuroendocrine prostate cancer: mechanistic insight and novel combination therapy approaches. Oncoscience 5(11-12):273-275, 2018. e-Pub 2018. PMID: 30652111.
Luo Y, Azad AK, Karanika S, Basourakos SP, Zuo X, Wang J, Yang L, Yang G, Korentzelos D, Yin J, Park S, Zhang P, Campbell JJ, Schall TJ, Cao G, Li L, Thompson TC. Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer 142(10):2163-2174, 2018. e-Pub 2018. PMID: 29277895.
Research Network CGA. The Immune Landscape of Cancer. Immunity 48(4):812-830.e14, 2018. e-Pub 2018. PMID: 29628290.
Research Network CGA. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173(2):371-385.e18, 2018. PMID: 29625053.
Research Network CGA. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173(2):338-354.e15, 2018. PMID: 29625051.
Research Network CGA. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 173(2):386-399.e12, 2018. PMID: 29625054.
Research Network CGA. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23(1):239-254.e6, 2018. PMID: 29617664.
Research Network CGA. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 173(2):400-416.e11, 2018. PMID: 29625055.
Research Network CGA. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell 173(2):355-370.e14, 2018. PMID: 29625052.
Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24(3):696-707, 2018. e-Pub 2017. PMID: 29138344.
Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121(1):69-76, 2018. e-Pub 2017. PMID: 28710901.
Liu Y, Tan X, Liu W, Chen X, Hou X, Shen D, Ding Y, Yin J, Wang L, Zhang H, Yu Y, Hou J, Thompson TC, Cao G. Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma. Chin J Cancer 37(1):2, 2018. e-Pub 2018. PMID: 29357946.
Thompson TC, Li L, Bradley BM. Combining enzalutamide with PARP inhibitors: Pharmaceutically. Oncotarget 8(55):93315-93316, 2017. PMID: None.
Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 10(480), 2017. e-Pub 2017. PMID: 28536297.
Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett 13(3):1949-1957, 2017. e-Pub 2017. PMID: 28454349.
Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18(8):1970-1981, 2017. PMID: 28228262.
Thompson TC, Li L. Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer. Mol Cell Oncol 4(4):e1321167, 2017. e-Pub 2017. PMID: 28819638.
Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem. e-Pub 2016. PMID: 27978798.
Shu X, Ye Y, Gu J, He Y, Davis JW, Thompson TC, Logothetis CJ, Kim J, Wu X. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis 37(10):965-71, 2016. e-Pub 2016. PMID: 27515962.
Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. e-Pub 2016. PMID: 27331874.
Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22(6):1520-30, 2016. e-Pub 2015. PMID: 26546618.
Sethna S, Chamakkala T, Gu X, Thompson TC, Cao G, Elliott MH, Finnemann SC. Regulation of Phagolysosomal Digestion by Caveolin-1 of the Retinal Pigment Epithelium is Essential for Vision. J Biol Chem. e-Pub 2016. PMID: 26814131.
Liu Y, Han X, Yu Y, Ding Y, Ni C, Liu W, Hou X, Li Z, Hou J, Shen D, Yin J, Zhang H, Thompson TC, Tan X, Cao G. A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression. Sci Rep 6:26689, 2016. e-Pub 2016. PMID: 27225192.
Reagan A, Gu X, Hauck SM, Ash JD, Cao G, Thompson TC, Elliott MH. Retinal Caveolin-1 Modulates Neuroprotective Signaling. Adv Exp Med Biol 854:411-8, 2016. PMID: 26427439.
Tu H, Gu J, Meng QH, Kim J, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget 6(39):41988-96, 2015. e-Pub 2015. PMID: 26515605.
Research Network CGA. The Molecular Taxonomy of Primary Prostate Cancer. Cell 163(4):1011-25, 2015. PMID: 26544944.
Yin J, Wang J, Pu R, Xin H, Li Z, Han X, Ding Y, Du Y, Liu W, Deng Y, Ji X, Wu M, Yu M, Zhang H, Wang H, Thompson TC, Ni W, Cao G. Hepatitis B virus combo mutations improve the prediction and active prophylaxis of hepatocellular carcinoma: a clinic-based cohort study. Cancer Prev Res (Phila) 8(10):978-88, 2015. e-Pub 2015. PMID: 26290395.
Kubo M, Satoh T, Tabata KI, Tsumura H, Iwamura M, Baba S, Thompson TC, Obata F. Enhanced central memory cluster of differentiation 8(+) and tumor antigen-specific T cells in prostate cancer patients receiving repeated in situ adenovirus-mediated suicide gene therapy. Mol Clin Oncol 3(3):515-521, 2015. e-Pub 2015. PMID: 26137259.
Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 67(3):470-9, 2015. e-Pub 2014. PMID: 25306226.
Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, Park S, Golstov AA, Tanimoto R, Li L, Thompson TC. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer 14:122, 2015. e-Pub 2015. PMID: 26084402.
Thompson TC, Li L. New targets for resistant prostate cancer. Oncotarget 5(19):8816-7, 2014. PMID: 25301740.
Li ML, Lin J, Hou JG, Xu L, Cui XG, Xu XX, Yu YW, Han X, Wang GM, Guo JM, Xu DF, Thompson TC, Cao GW, Zhang HW. Environmental and Psycho-social Factors Related to Prostate Cancer Risk in the Chinese Population: a Case-control Study. Biomed Environ Sci 27(9):707-717, 2014. PMID: 25256860.
Karanika S, Karantanos T, Li L, Corn PG, Thompson TC. DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene 0. e-Pub 2014. PMID: 25132269.
Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. Sci Signal 7(326):ra47, 2014. e-Pub 2014. PMID: 24847116.
Karantanos T, Tanimoto R, Edamura K, Hirayama T, Yang G, Golstov AA, Wang J, Kurosaka S, Park S, Thompson TC. Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer. Int J Cancer 134(8):2003-13, 2014. e-Pub 2013. PMID: 24590455.
Fujita T, Satoh T, Timme TL, Hirayama T, Zhu JX, Kusaka N, Naruishi K, Yang G, Goltsov A, Wang J, Vlachaki MT, Teh BS, Brian Butler E, Thompson TC. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. Urol Oncol 32(2):92-100, 2014. e-Pub 2013. PMID: 23433894.
Karanika S, Karantanos T, Yin J, Li L, Thompson TC. Novel anti-androgen receptor signaling agents: understanding the mechanisms of resistance. Asian Journal of Urology:30-39, 2014. PMID: None.
Tan X, Wang Y, Han Y, Chang W, Su T, Hou J, Xu D, Yu Y, Ma W, Thompson TC, Cao G. Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression. Br J Cancer 109(12):3105-15. doi: 10.1038/bjc.2013.669, 2013. e-Pub 2013. PMID: 24157827.
Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32(49):doi: 10.1038/onc.2013.206, 2013. e-Pub 2013. PMID: 23752182.
Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, Bartolucci G, Danza G, Adam RM, Thompson TC, Lisanti MP, Freeman MR, Di Vizio D. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumor progression. J Pathol 231(1):77-87, 2013. e-Pub 2013. PMID: 23729330.
Karantanos T, Thompson TC. GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer. Cancer Cell 24(1):11-13, 2013. PMID: 23845440.
Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol 7(3):484-96, 2013. e-Pub 2012. PMID: 23333597.
Tahir SA, Yang G, Goltsov A, Song KD, Ren C, Wang J, Chang W, Thompson TC. Caveolin-1LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res 73(6):1900-11, 2013. e-Pub 2013. PMID: 23302227.
Tahir SA, Kurosaka S, Tanimoto R, Goltsov AA, Park S, Thompson TC. Serum caveolin-1 as a biomarker of drug response and therapeutic target in association with tyrosine kinase inhibitor treatment in prostate cancer models. Cancer Biol Ther 14(2):117-26, 2013. e-Pub 2012. PMID: 23114714.
Kuo SR, Tahir SA, Park S, Thompson TC, Coffield S, Frankel AE, Liu JS. Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. Hybridoma (Larchmt) 31(2):77-86, 2012. PMID: 22509911.
Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, Thompson TC. Caveolin-1 upregulation contributes to c-myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10(2):218-29, 2012. e-Pub 2011. PMID: 22144662.
Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC. GLIPR1 suppressess prostate cancer through targeted oncoprotein destruction. Cancer Res 71(24):7694-704, 2011. e-Pub 2011. PMID: 22025562.
Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17(22):7174-82, 2011. e-Pub 2011. PMID: 21933889.
Floryk D, Kurosaka S, Tanimoto R, Yang G, Goltsov A, Park S, Thompson TC. Castration-induced changes in mouse epididymal white adipose tissue molecular and cellular endocrinology. Mol Cell Endocrinol 345(1-2):58-67, 2011. e-Pub 2011. PMID: 21782885.
Tabata K, Kurosaka S, Watanabe M, Edamura K, Satoh T, Yang G, Abdelfattah E, Wang J, Goltsov A, Floryk D, Thompson TC. Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Ther 18(10):969-78, 2011. e-Pub 2011. PMID: 21512508.
Thompson TC. Turning reciprocal feedback regulation into combination therapy. Cancer Cell 19(19):697-699, 2011. PMID: 21665144.
Gao Y, Ishiyama H, Sun M, Brinkman KL, Wang X, Zhu Z, Mai W, Huang Y, Floryk D, Ittmann M, Thompson TC, Butler EB, Xu B, The BS. The akylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol(15):6-39, 2011. PMID: None.
Gao Y, Ishiyama H, Sun M, Brinkman KL, Wang X, Zhu J, Mai W, Huang Y, Floryk D, Ittmann M, Thompson TC, Butler EB, Xu B, Teh BS. The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol 6:39, 2011. e-Pub 2011. PMID: 21496273.
Yang G, Park S, Cao G, Goltsov A, Ren C, Truong LD, Demayo F, Thompson TC. MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice. Exp Mol Pathol 89(1):9-19, 2010. e-Pub 2010. PMID: 20399205.
Thompson TC. Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential. Yonsei Med J 51(4):479-83, 2010. PMID: 20499410.
Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 70(9):1020-35, 2010. PMID: 20209490.
Thompson TC. Grappling with the androgen receptor: a new approach for treating advanced prostate cancer. Cancer Cell 17(6):525-6, 2010. PMID: 20541694.
Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 13(1):6-11, 2010. e-Pub 2009. PMID: 19581923.
Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res 2:111-122, 2010. e-Pub 2010. PMID: 21188102.
Tahir SA, Park S, Thompson TC. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther 8(23):2286-96, 2009. e-Pub 2009. PMID: 19923922.
Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 7(11):1781-91, 2009. e-Pub 2009. PMID: 19903767.
Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K, Fattah EA, Rajagopalan K, Timme TL, Park S, Kurosaka S, Edamura K, Tanimoto R, Demayo FJ, Goltsov AA, Thompson TC. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res 7(9):1446-55, 2009. e-Pub 2009. PMID: 19737975.
Tabata K, Watanabe M, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, Wang J, Goltsov A, Floryk D, Soni SD, Kadmon D, Thompson TC. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis 12(3):301-9, 2009. e-Pub 2008. PMID: 19104507.
Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, Shine D, Kadmon D, Thompson T, Miles BJ, Ittmann MM, Rowley D. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res 14(23):7593-603, 2008. PMID: 19047084.
Floryk D, Thompson TC. Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. Int J Cancer 123(10):2294-302, 2008. PMID: 18712736.
Ayala G, Yan J, Li R, Ding Y, Thompson TC, Mims MP, Hayes TG, MacDonnell V, Lynch RG, Frolov A, Miles BJ, Wheeler TM, Harper JW, Tsai MJ, Ittmann MM, Kadmon D. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated akt. Clin Cancer Res 14(22):7511-8, 2008. PMID: 19010869.
Floryk D, Thompson TC. Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett 266(2):216-26, 2008. e-Pub 2008. PMID: 18395973.
Yang G, Timme TL, Naruishi K, Fujita T, Fattah el MA, Cao G, Rajagopalan K, Rajocopolan K, Troung LD, Thompson TC. Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol 84(2):131-40, 2008. e-Pub 2007. PMID: 18358473.
Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, Fattah el MA, Kadmon D, Thompson TC. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 68(3):731-9, 2008. PMID: 18245473.
Li L, Abdel Fattah E, Cao G, Ren C, Yang G, Goltsov AA, Chinault AC, Cai WW, Timme TL, Thompson TC. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res 68(2):434-43, 2008. PMID: 18199537.
Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ, Wang RF. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13(23):6947-58, 2007. PMID: 18056169.
Thompson TC. Suppression of tumor suppressors in prostate cancer: the emergence of a novel oncogenic pathway. Cancer Cell 12(5):405-7, 2007. PMID: 17996641.
Yang G, Addai J, Wheeler TM, Frolov A, Miles BJ, Kadmon D, Thompson TC. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol 38(11):1688-95, 2007. PMID: 17707459.
Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Frolov A, Brenner MK, Kadmon D, Thompson TC. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther 14(10):819-27, 2007. PMID: 17627292.
Li R, Erdamar S, Dai H, Wheeler TM, Frolov A, Scardino PT, Thompson TC, Ayala GE. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol 38(10):1501-7, 2007. PMID: 17597184.
Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, Manabe D, Thompson TC, Kumon H. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 15(4):834-40, 2007. PMID: 17327829.
Thompson TC, Rodriguez R. Gene therapy prolongs PSA doubling time in prostate cancer patients. Mol Ther 15(3):442-3, 2007. PMID: 17311030.
Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Ren C, Yang G, Goltsov A, Wang H, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Ther 14(3):227-36, 2007. PMID: 17024109.
Lai HH, Boone TB, Thompson TC, Smith CP, Somogyi GT. Using caveolin-1 knockout mouse to study impaired detrusor contractility and disrupted muscarinic activity in the aging bladder. Urology 69(2):407-11, 2007. PMID: 17320698.
Thompson TC. Exploiting the complex biology of prostate cancer. Cancer Biol Ther 5(11):1573-6, 2006. PMID: 17172813.
Ren C, Ren CH, Li L, Goltsov AA, Thompson TC. Identification and characterization of RTVP1/GLIPR1-like genes, a novel p53 target gene cluster. Genomics 88(2):163-72, 2006. PMID: 16714093.
Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 12(16):4872-5, 2006. PMID: 16914574.
Naruishi K, Timme TL, Kusaka N, Fujita T, Yang G, Goltsov A, Satoh T, Ji X, Tian W, Abdelfattah E, Men T, Watanabe M, Tabata K, Thompson TC. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther 13(7):658-63, 2006. PMID: 16485011.
Fujita T, Teh BS, Timme TL, Mai WY, Satoh T, Kusaka N, Naruishi K, Fattah EA, Aguilar-Cordova E, Butler EB, Thompson TC. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 65(1):84-90, 2006. PMID: 16472937.
Ayala GE, Dai H, Tahir SA, Li R, Timme T, Ittmann M, Frolov A, Wheeler TM, Rowley D, Thompson TC. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res 66(10):5159-64, 2006. PMID: 16707439.
Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, Frolov A, Wheeler TM, Miles BJ, Rauen K, Teh BS, Butler EB, Thompson TC, Kadmon D. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 13(4):716-28, 2006. PMID: 16480930.
Ayala GE, Dai H, Li R, Ittmann M, Thompson TC, Rowley D, Wheeler TM. Bystin in perineural invasion of prostate cancer. Prostate 66(3):266-72, 2006. PMID: 16245277.
Koh MS, Ittmann M, Kadmon D, Thompson TC, Leach FS. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther 5(1):78-83, 2006. PMID: 16357515.
Saika T, Kusaka N, Mouraviev V, Satoh T, Kumon H, Timme Thompson TC. Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model. Cancer Gene Ther 13(1):91-8, 2006. PMID: 16052232.
Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D, Ayala G. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 65(3):276-86, 2005. PMID: 16015593.
Haqq C, Li R, Khodabakhsh D, Frolov A, Ginzinger D, Thompson T, Wheeler T, Carroll P, Ayala G. Ethnic and racial differences in prostate stromal estrogen receptor alpha. Prostate 65(2):101-9, 2005. PMID: 15880569.
Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 173(6):1923-5, 2005. PMID: 15879782.
Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 103(6):1186-94, 2005. PMID: 15712208.
Lai HH, Boone TB, Yang G, Smith CP, Kiss S, Thompson TC, Somogyi GT. Loss of caveolin-1 expression is associated with disruption of muscarinic cholinergic activities in the urinary bladder. Neurochem Int 45(8):1185-93, 2004. PMID: 15380628.
Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10(19):6572-8, 2004. PMID: 15475446.
Rao XM, Tseng MT, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson TC, Brenner MK, McMasters KM, Zhou HS. E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther 11(9):585-93, 2004. PMID: 15338010.
Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, Rowley D. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64(17):6082-90, 2004. PMID: 15342391.
Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 28(7):928-34, 2004. PMID: 15223964.
Satoh T, Teh BS, Timme TL, Mai WY, Gdor Y, Kusaka N, Fujita T, Pramudji CK, Vlachaki MT, Ayala G, Wheeler T, Amato R, Miles BJ, Kadmon D, Butler EB, Thompson TC. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 59(2):562-71, 2004. PMID: 15145177.
Saika T, Satoh T, Kusaka N, Ebara S, Mouraviev VB, Timme TL, Thompson TC. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther 11(5):317-24, 2004. PMID: 15044961.
Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 58(5):1520-9, 2004. PMID: 15050332.
Yang G, Addai J, Tian WH, Frolov A, Wheeler TM, Thompson TC. Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res 64(6):2076-82, 2004. PMID: 15026346.
Ren C, Li L, Yang G, Timme TL, Goltsov A, Ren C, Ji X, Addai J, Luo H, Ittmann MM, Thompson TC. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res 64(3):969-76, 2004. PMID: 14871827.
Teh BS, Ayala G, Auilar L, W-Y M, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson TC, Aguilar-Cordova E, Butler EB. Phase I/II trial evaluating combined intensity modulated radiation therapy (IMRT) and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--an interim report on PSA response and biopsy data. Int J Radiation Oncology Biol Phys 58:1520-1529, 2004. PMID: None.
Gdor Y, Timme TL, Kadmon D, Miles BJ, Thompson TC. Strategies for prostate cancer gene therapy. Am J Cancer 3:79-95, 2004. PMID: None.
Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23(24):9389-404, 2003. PMID: 14645548.
Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G, Wang J, Mouraviev V, Cao G, Fattah el MA, Thompson TC. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res 63(22):7853-60, 2003. PMID: 14633713.
Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, Frolov A, Ayala G, Wheeler TM, Thompson TC. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 9(10 Pt 1):3653-9, 2003. PMID: 14506154.
Wen Y, Giri D, Yan DH, Spohn B, Zinner RG, Xia W, Thompson TC, Matusik RJ, Hung MC. Prostate-specific antitumor activity by probasin promoter-directed p202 expression. Mol Carcinog 37(3):130-7, 2003. PMID: 12884364.
Zhao T, Rao XM, Xie X, Li L, Thompson TC, McMasters KM, Zhou HS. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 63(12):3073-8, 2003. PMID: 12810631.
Hillman GG, Xu M, Wang Y, Wright JL, Lu X, Kallinteris NL, Tekyi-Mensah S, Thompson TC, Mitchell MS, Forman JD. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Hum Gene Ther 14(8):763-75, 2003. PMID: 12804139.
Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, Goltsov A, Park SH, Men T, Kusaka N, Tian W, Ren C, Wang H, Kadmon D, Cai WW, Chinault AC, Boone TB, Bradley A, Thompson TC. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol 162(4):1241-8, 2003. PMID: 12651616.
Satoh T, Yang G, Egawa S, Addai J, Frolov A, Kuwao S, Timme TL, Baba S, Thompson TC. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97(5):1225-33, 2003. PMID: 12599229.
Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J, Ren C, Kusaka N, Mouraviev V, Thompson TC. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 14(2):91-101, 2003. PMID: 12614561.
Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 8(11):3419-26, 2002. PMID: 12429629.
Vlachaki MT, Hernandez-Garcia A, Ittmann M, Chhikara M, Aguilar LK, Zhu X, Teh BS, Butler EB, Woo S, Thompson TC, Barrera-Saldana H, Aguilar-Cordova E, The BS. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther 6(3):342-8, 2002. PMID: 12231170.
Gdor Y, Timme TL, Miles BJ, Kadmon D, Thompson TC. Gene therapy for prostate cancer. Expert Rev Anticancer Ther 2(3):309-321, 2002. PMID: 12113054.
Ren C, Li L, Goltsov AA, Timme TL, Tahir SA, Wang J, Garza L, Chinault AC, Thompson TC. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol 22(10):3345-57, 2002. PMID: 11971968.
Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Park SH, Thompson T, Karsenty G, Bradley A, Donehower LA. p53 mutant mice that display early ageing-associated phenotypes. Nature 415(6867):45-53, 2002. PMID: 11780111.
Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. Prostate Cancer Prostatic Dis 5(4):316-25, 2002. PMID: 12627218.
Teh BS, Aguilar-Cordova E, Vlachaki MT, Aguilar L, Mai WY, Caillouet J, Davis M, Miles B, Kadmon D, Ayala G, Lu HH, Chiu JK, Carpenter LS, Woo SY, Grant WH, Wheeler T, Thompson TC, Butler EB. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist 7(5):458-66, 2002. PMID: 12401909.
Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C, Yuan Y, Tahir SA, Timme TL, Thompson TC. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin Cancer Res 7(12):4272-9, 2001. PMID: 11751529.
Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G, Adler HL, Kernen K, Pramudji CK, Satoh T, Gdor Y, Ren C, Ayala G, Wheeler TM, Butler EB, Kadmon D, Thompson TC. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12(16):1955-67, 2001. PMID: 11686937.
Vlachaki MT, Chhikara M, Aguilar L, Zhu X, Chiu KJ, Woo S, Teh BS, Thompson TC, Butler EB, Aguilar-Cordova E. Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys 51(4):1008-17, 2001. PMID: 11704325.
Cabeza-Arvelaiz Y, Thompson TC, Sepulveda JL, Chinault AC. LAPSER1: a novel candidate tumor suppressor gene from 10q24.3. Oncogene 20(46):6707-17, 2001. PMID: 11709705.
Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC. Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 20(31):4169-79, 2001. PMID: 11464283.
Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, Ratliff TL. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst 93(13):998-1007, 2001. PMID: 11438565.
Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61(11):4386-92, 2001. PMID: 11389065.
Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, Thompson TC. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61(10):3882-5, 2001. PMID: 11358800.
Chhikara M, Huang H, Vlachaki MT, Zhu X, Teh B, Chiu KJ, Woo S, Berner B, Smith EO, Oberg KC, Aguilar LK, Thompson TC, Butler EB, Aguilar-Cordova E. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 3(4):536-42, 2001. PMID: 11319915.
Sukin SW, Chhikara M, Zhu X, Ayala G, Aguilar LK, O'Brian Smith E, Miles BJ, Thompson TC, Kadmon D, Aguilar-Cordova E. In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol Ther 3(4):500-6, 2001. PMID: 11319910.
Nasu Y, Bangma CH, Hull GW, Yang G, Wang J, Shimura S, McCurdy MA, Ebara S, Lee HM, Timme TL, Thompson TC. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Dis 4(1):44-55, 2001. PMID: 12497062.
Teh BS, Aguillar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, Miles B, Kadmon D, Mai WY, Caillouet J, Davis M, Ayala G, Wheeler T, Brady J, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Butler EB. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys 51(3):605-613, 2001. PMID: None.
Thaller C, Shalev M, Frolov A, Eichele G, Thompson TC, Williams RH, Dillioglugil O, Kadmon D. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol 18(22):3804-8, 2000. PMID: 11078493.
Shalev M, Thompson TC, Frolov A, Lippman SM, Hong WK, Fritsche H, Kadmon D. Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res 6(10):3845-9, 2000. PMID: 11051228.
Hull GW, Mccurdy MA, Nasu Y, Bangma CH, Yang G, Shimura S, Lee HM, Wang J, Albani J, Ebara S, Sato T, Timme TL, Thompson TC. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res 6(10):4101-9, 2000. PMID: 11051263.
Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 60(20):5857-61, 2000. PMID: 11059783.
Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res 6(9):3430-3, 2000. PMID: 10999725.
Ayala G, Wheeler TM, Shalev M, Thompson TC, Miles B, Aguilar-Cordova E, Chakraborty S, Kadmon D. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol 31(7):866-70, 2000. PMID: 10923926.
Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN, Thompson TC. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 19(29):3256-65, 2000. PMID: 10918582.
Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT, Miles BJ. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 163(6):1747-50, 2000. PMID: 10799174.
Kwabi-Addo B, Thompson TC, Ittmann M. Absence of PTEN/MMAC1 pseudogene in mice. DNA Cell Biol 19(5):301-5, 2000. PMID: 10855797.
Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 60(7):1927-33, 2000. PMID: 10766182.
Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC, Harper JW. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 19(18):2186-93, 2000. PMID: 10822368.
Lotan Y, Xu XC, Shalev M, Lotan R, Williams R, Wheeler TM, Thompson TC, Kadmon D. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 18(1):116-21, 2000. PMID: 10623701.
Shaker MR, Yang G, Timme TL, Park SH, Kadmon D, Ren C, Ji X, Lee HM, Sehgal I, Anzano M, Sporn MB, Thompson TC. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis 18(5):429-38, 2000. PMID: 11467776.
Paielli DL, Wing MS, Rogulski KR, Gilbert JD, Kolozsvary A, Kim JH, Thompson TC, Freytag SG. Evaluation of the biodistribution, persistence, toxicity and potential of germ line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 1:263-274, 2000. PMID: None.
Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59(22):5719-23, 1999. PMID: 10582690.
Erdamar S, Yang G, Harper JW, Lu X, Kattan MW, Thompson TC, Wheeler TM. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol 12(8):751-5, 1999. PMID: 10463475.
Thompson TC, Timme TL, Li L, Goltsov A. Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 4(4):233-7, 1999. PMID: 14634273.
Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC, Scardino PT. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 10(7):1239-49, 1999. PMID: 10340555.
Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J, McCurdy MA, Shimura S, Yang G, Timme TL, Thompson TC. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 6(3):338-49, 1999. PMID: 10435084.
Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell 10(2):407-16, 1999. PMID: 9950685.
Hall SJ, Mutchnik SE, Yang G, Timme TL, Nasu Y, Bangma CH, Woo SL, Shaker M, Thompson TC. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther 6(1):54-63, 1999. PMID: 10078964.
Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161(1):182-7, 1999. PMID: 10037394.
Thompson TC, Timme TL, Li L, Goltsov A, Yang G. A complex and provocative therapeutic target in prostate cancer and potentially other maliganancies. Emerging Therapeutic Targets 3:337-347, 1999. PMID: None.
Thompson TC. In situ gene therapy for prostate cancer. Oncol Res 11(1):1-8, 1999. PMID: 10451026.
Sehgal I, Thompson TC. Neuropeptides induce Mr 92,000 type IV collagenase (matrix metalloprotease-9) activity in human prostate cancer cell lines. Cancer Res 58(19):4288-91, 1998. PMID: 9766654.
Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4(9):1062-4, 1998. PMID: 9734401.
Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4(8):1873-80, 1998. PMID: 9717814.
Hampel OZ, Kattan MW, Yang G, Haidacher SJ, Saleh GY, Thompson TC, Wheeler TM, Marcelli M. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol 159(6):2220-5, 1998. PMID: 9598573.
Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res 58(6):1285-90, 1998. PMID: 9515817.
Timme TL, Hall SJ, Barrios R, Woo SL, Aguilar-Cordova E, Thompson TC. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Ther 5(2):74-82, 1998. PMID: 9570298.
Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol 152(2):591-6, 1998. PMID: 9466586.
Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT, Thompson TC. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 82(1):168-75, 1998. PMID: 9428494.
Hall SJ, Thompson TC. Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines. Clin Exp Metastasis 15(6):630-8, 1997. PMID: 9344047.
Yang G, Timme TL, Park SH, Wu X, Wyllie MG, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. Prostate 33(3):157-63, 1997. PMID: 9365542.
Yang G, Timme TL, Park SH, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: I. Induction of neuronal phenotypes. Prostate 33(3):151-6, 1997. PMID: 9365541.
Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 3(8):1389-97, 1997. PMID: 9815823.
Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 70(2):183-7, 1997. PMID: 9009158.
Bosland MC, Chung LWK, Greenberg NM, S-M H, Isaacs JT, Lane K, Peehl DM, Thompson TC, van Steenbrugge GJ, van Weerden WM. Recent advances in the development of animal and cell culture models for prostate cancer research: A minireview. Urol Oncol 2:99-128, 1997. PMID: None.
Yang G, Wheeler TM, Kattan MW, Scardino PT, Thompson TC. Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer 78(6):1267-71, 1996. PMID: 8826950.
Stapleton AM, Williams RH, Timme TL, Yang G, Truong LD, Thompson TC. Human cytomegalovirus is not implicated in benign prostatic hyperplasia: a study using immunohistochemistry and the polymerase chain reaction. J Urol 156(2 Pt 1):542-5, 1996. PMID: 8683733.
Sehgal I, Baley PA, Thompson TC. TGF-β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 56(14):3359-65, 1996. PMID: 8764134.
Timme TL, Yang G, Rogers E, Kadmon D, Morganstern JP, Park SH, Thompson TC. Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest 74(4):747-60, 1996. PMID: 8606485.
Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC. Reduced expression of TGF-β receptor type II in human prostate cancer: an immunohistochemical analysis. Clin Cancer Res 2(4):635-40, 1996. PMID: 9816213.
Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SL, Thompson TC. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7(4):515-23, 1996. PMID: 8800746.
Yang G, Stapleton AM, Wheeler TM, Truong LD, Timme TL, Scardino PT, Thompson TC. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 2(2):399-401, 1996. PMID: 9816183.
Todd D, Yang G, Brown RW, Cao J, Agati VD, Thompson TC, Truong LD. Apoptosis in renal cell carcinoma: Detection by in situ end-labelling of fragmented DNA and correlation with other prognostic factors. Hum Pathol 27:1012-1017, 1996. PMID: None.
Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73(5):628-35, 1995. PMID: 7474936.
Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1(10):1111-8, 1995. PMID: 9815901.
Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 52(5):403-13, 1995. PMID: 7538321.
Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 10(5):869-79, 1995. PMID: 7534899.
Greene DR, Taylor SR, Aihara M, Yoshida K, Egawa S, Park SH, Timme TL, Yang G, Scardino PT, Thompson TC. DNA ploidy and clonal selection in ras + myc-induced mouse prostate cancer. Int J Cancer 60(3):395-9, 1995. PMID: 7829250.
Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G, Thompson TC. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer 75(2):522-9, 1995. PMID: 7529128.
Timme TL, Yang G, Truong LD, Kadmon D, Park SH, Thompson TC. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol 13(6):324-8, 1995. PMID: 9116750.
Eastham JA, Hall SJ, Sehgal I, Wang J, Connel-Crowley L, Elledge SJ, W-W Z, Harper, JW, Thompson TC. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151-5155, 1995. PMID: None.
Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery Jr CA, Park SH, Thompson TC, Ford RJ, Bradley A. Effects of genetic background of tumorigenesis in p53-deficient mice. Mol Carcinog 14:16-22, 1995. PMID: None.
Thompson TC, Timme TL, Park SH, Ren C, Baley PA, Eastham JA, Sehgal I, Yang G, Kadmon D. Tissue and cell-cell interactions in prostate cancer progression. Cancer 75(Suppl):1885-1891, 1995. PMID: None.
Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?. J Urol 152(5 Pt 2):1843-9, 1994. PMID: 7523732.
Timme TL, Thompson TC. Rapid allelotype analysis of p53 knockout mice. Biotechniques 17(3):460, 462-3, 1994. PMID: 7818898.
Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 25(8):797-801, 1994. PMID: 7520020.
Greene DR, Rogers E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA, Thompson TC, Scardino PT. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 151(5):1301-7, 1994. PMID: 8158775.
Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology 134(3):1039-45, 1994. PMID: 8119140.
Wheeler TM, Rogers E, Aihara M, Scardino PT, Thompson TC. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. J Cell Biochem Suppl 19:202-7, 1994. PMID: 7823593.
Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 53(19):4461-5, 1993. PMID: 8402613.
Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 24(1):4-9, 1993. PMID: 7678092.
Thompson TC, Timme TL, Kadmon D, Park SH, Egawa S, Yoshida K. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog 7(3):165-79, 1993. PMID: 8489712.
Thompson TC, Egawa S, Kadmon D, Miller GJ, Timme TL, Scardino PT, Park SH. Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas. J Steroid Biochem Mol Biol 43(1-3):79-85, 1992. PMID: 1525069.
Lu X, Park SH, Thompson TC, Lane DP. Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70(1):153-61, 1992. PMID: 1623518.
Egawa S, Kadmon D, Miller GJ, Scardino PT, Thompson TC. Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol Carcinog 5(1):52-61, 1992. PMID: 1543541.
Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC. Elevated transforming growth factor-β1 and β3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol 5(4):503-13, 1991. PMID: 1922083.
Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH. Experimental oncogene induced prostate cancer. Cancer Surv 11:55-71, 1991. PMID: 1726789.
Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56(6):917-30, 1989. PMID: 2538247.
Compere SJ, Baldacci P, Sharpe AH, Thompson TC, Land H, Jaenisch R. The ras and myc oncogenes cooperate in tumor induction in many tissues when introduced into midgestation mouse embryos by retroviral vectors. Proc Natl Acad Sci USA 86:2224-2228, 1989. PMID: None.
Mills JS, Needham M, Thompson TC, Parker MG. Androgen-regulated expression of secretory protein synthesis in mouse ventral prostate. Mol Cell Endocrinol 53(1-2):111-8, 1987. PMID: 3666286.
Thompson TC, Zhau HY, Chung LW. Catecholamines are involved in the growth and expression of prostatic binding protein by rat ventral prostatic tissues. Prog Clin Biol Res 239:239-48, 1987. PMID: 2821548.
Thompson TC, Cunha GR, Shannon JM, Chung LW. Androgen-induced biochemical responses in epithelium lacking androgen receptors: characterization of androgen receptors in the mesenchymal derivative of urogenital sinus. J Steroid Biochem 25(5A):627-34, 1986. PMID: 3795942.
Thompson TC, Chung LW. Regulation of overgrowth and expression of prostatic binding protein in rat chimeric prostate gland. Endocrinology 118(6):2437-44, 1986. PMID: 2422020.
Thompson TC, Chung LWK. Evidence for a urogenital sinus-derived growth factor(s). Ann NY Acad Sci 438:582-5, 1985. PMID: None.
Chung LWK, Matsuura J, Rocco AK, Thompson TC, Miller GJ, Runner MN. Tissue interactions and prostatic growth. Ann NY Acad Sci 438:582-585, 1985. PMID: None.
Thompson TC, Chung LW. Extraction of nuclear androgen receptors by sodium molybdate from normal rat prostates and prostatic tumors. Cancer Res 44(3):1019-26, 1984. PMID: 6692389.
Thompson TC, Chung LW. Evidence for a soluble fetal urogenital sinus-derived growth factor(s). Ann N Y Acad Sci 438:582-5, 1984. PMID: 6085457.
Chung LW, Matsuura J, Rocco AK, Thompson TC, Miller GJ, Runner MN. A new mouse model for prostatic hyperplasia: induction of adult prostatic overgrowth by fetal urogenital sinus implants. Prog Clin Biol Res 145:291-306, 1984. PMID: 6201880.
Neubauer BL, Chung LW, McCormick KA, Taguchi O, Thompson TC, Cunha GR. Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 96(6):1671-6, 1983. PMID: 6853598.
Chung LW, Matsuura J, Thompson TC, Chao RC. A new approach to regulation of prostatic growth: interactions between embryonic urogenital sinuses and adult prostate in situ. Proc West Pharmacol Soc 25:141-5, 1982. PMID: 6889738.
Chung LW, Thompson TC, Breitweiser K. Sensitive biochemical methods to distinguish hormone dependent and independent Dunning tumors of prostatic origin. Proc West Pharmacol Soc 24:305-10, 1981. PMID: 6265951.
Vykoukal J, Chen Y, Hong MJ, Zuo M, Krishna H, Katayama H, Irajizad E, Wu R, León-Letelier RA, Dennison JB, Gutierrez AM, Paulucci-Holthauzen A, Thompson TC, Rusling L, Cai Y, Hsiao FC, Park S, Arun B, Hanash S, Fahrmann JF. Vesicle-mediated mitochondrial clearance underlies an actionable metabolic vulnerability in triple-negative breast cancer. bioRxiv None(None):None. PMID: None.

Manuals, Teaching Aids, Other Teaching Publications

Kadmon D, Thompson TC. Mechanisms of developing androgen independence in carcinoma of the prostate. None, 2007.

Editorials

Thompson TC. Cancer Biology and the Mutant Mouse: New Methods, New Models, New Insights (Meeting News). Investigational Drugs (ID) Weekly Highlights, Current Drugs Ltd, London, UK:26-29, 1999. PMID: None.
Thompson TC, Kadmon D, Timme TL, Egawa S, Krebs T, Merz VW, Park SH, Ripoll E, Scardino PT. Experimental, oncogene-induced prostate cancer. Baylor Urologic Update, 1991. PMID: None.
Tindall DJ, Thompson TC, Buttyan R. Molecular biology: understanding methods and applications. AUA Annual Meeting, Text for Postgraduate Course, 1990. PMID: None.
Thompson TC. Uncoupling of growth and differentiation in rat ventral prostate: Involvement of 5-hydroxytryptamine and norepinephrine. None, 1985. PMID: None.

Abstracts

Pilie P, Tidwell R, Viscuse P, Subudhi S, Corn P, Tu S, Araujo J, Zurits A, Wang J, Efstathiou E, Deinert J, Logothetis C, Thompson T, Aparicio A. Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel-carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC). 2023 GU ASCO, 2023. PMID: None.
Siddiqui BA, Thompson TC, Pilié PG, Aparicio AM, Logothetis CJ, Subudhi SK. Resistance to Immune Checkpoint Therapy (ICT) in Aggressive Variant Prostate Cancer (AVPC). 13th Annual Multi-Institutional Prostate Cancer Program Retreat, 2020. PMID: None.
Gregg JR, Fahrmann J, Vykoukal J, Davis J, Kim J, Hanash S, and Thompson TC. Discovery and Modification of a Non-invasive Metabolomics-Based Signature of Prostate Cancer Progression in Men Enrolled on Active Surveillance. 13th Annual Multi-Institutional Prostate Cancer Program Retreat, 2020. PMID: None.
Tang Z, Pilie PG, Park S, Wu C, Dong Z, Yap TA, Corn PG, Thompson TC. Inhibitors of ATR lead to innate immune pathway activation and enhanced response to immune therapy. The Society for Immunotherapy of Cancer, National Harbor, MD, 2019. PMID: None.
Gregg JR, Fahrmann J, Peterson C, Vykoukal J, Hanash S, Davis J, Kim J, Thompson TC. Proteomic-based biomarkers for risk of progression in early prostate cancer. 18th Annual Meeting of the Society of Urologic Oncology, 2017. PMID: None.
Aparicio AM, Xiao L, Tapia EL, Hoang A, Ramesh N, Wu W, Chancoco H, Heath EI, Efstathiou E, Thompson TC, Troncoso P, Broom BM, Zurita AJ, Navin N, Logothetis C, Corn PG. The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC). American Society of Clinical Oncology, 2017. PMID: None.
Fahrmann, J, Vykoukal J, Basourakos S, Wang J, Dennison J, Murage E, Kim J, Thompson TC, Hanash S. Metabolomics identifies a caveolin-1-associated plasma glycosphingolipid and sphingomyelin signature that differentiates aggressive from indolent prostate cancer in an active surveillance cohort. AACR Annual Meeting Washington DC, 2017. PMID: None.
Basourakos S, Davis J, Chapin BF, Ward J, Pettaway C, Pisters L, Achim M, Wang X, Choi S, Kuban DA, Troncoso P, Logothetis C, Thompson TC, Kim J. Plasma caveolin-1 predicts disease reclassification in men with early stage prostate cancer in active surveillance. 2016 ASCO Annual Meeting, Chicago, IL, 2016. PMID: None.
Corn PG, Tapia E, Xiao L, Heath EI, Chancoco H, Hoang A, Efstathiou E, Thompson TC, Troncoso P, Logothetis C, Aparicio A. Confirmatory analysis to determine associations between platinum-sensitivity, molecular signature of combined tumor suppressor defects and aggressive variant prostate carcinomas (AVPC). American Society of Clinical Oncology, 2016. PMID: None.
Karantanos T, Song KD, Wang J, Masato D, Yang G, Park S, Wenling Z, Thompson TC. Caveolin-1 activates lipid synthesis and promotes prostate cancer growth following androgen deprivation. 20th Annual PCF Scientific Retreat, National Harbor, MD, 2013. PMID: None.
Karantanos T, Hirayama T, Wang J, Goltsov AA, Park S, Thompson TC. Caveolin-1 monoclonal antibody and 3BrPA combined therapy targeting aerobic glycolysis in prostate cancer. Keystone Symposia, 2013. PMID: None.
Thompson TC, Li L, Yang G, Ren C, Chang W, Hirayama T, Kim SM, Lee JS, Troncoso P, Park S. c-Myb and its targets as drivers in prostate cancer progression. The 6th Severence- MD Anderson Cancer Center Joint Symposium - "Personalized Cancer Therapy and Prevention.", 2012. PMID: None.
Elliott, MH, Dozmorov M, Li X, Iqbal H, McClellan M, Wren JD, Cao G, Thompson TC, Ueffing M, Jauck SM. Insights into caveolin-1 function: quantitative proteomic analysis of a novel retina-specific knockout mouse model. ARVO 2012, Translational Research: Seeing the Possibilities, 2011. PMID: None.
Thompson TC, Li L, Ren C, Yang G, Goltsov A, Abdel-Fattah E. Glioma pathogenesis-related protein 1, a tumor suppressor that stimulates oncoprotein destruction. 7th Annual National Symposium on Prostate Cancer, Clark Atlanta University, 2011. PMID: None.
Thompson TC, Li L, Ren C, Yang G, Goltsov A, Abdel-Fattah E. GLIPR1 suppresses prostate cancer through targeted oncoprotein destruction. The 5th Severence-MD Anderson Cancer Center Joint Symposium- "Personalized Cancer Therapy and Prevention", 2011. PMID: None.
Carthon B, Tahir S, Yang G, Wan X, Yang J, Tanimoto R, Kurosaka S, Park S, Goltsov A, Traoncoso P, Araujo J, Wen S, Gallick G, Navone N, Logothetis C, Thompson TC. Caveolin-1 as a biomarker of osteoblast activation and Src family kinase/Abl inhibition in castrate-resistant prostate cancer. United States Department of Defense-Innovative Minds in Prostate Cancer Today (DOD-IMPACT) Conference, 2011. PMID: None.
Thompson TC, Li L, Ren C, Yang G, Goltsov A, E-M A. Glioma pathogenesis-relate protein 1, a tumor suppressor that stimulates oncoprotein destruction. United States Departmetn of Defense-Innovative Minds in Prostate CAncer Today (DOD-IMPACT) Conference, 2011. PMID: None.
Carthon B, Tahir S, Araujo J, Wen S, Gallick G, Logothetis C, Thompson TC. Caveolin-1 as a biomarker of Src kinase inhibition in castration resistant prostate cancer. 2011 ASCO Genitourinary Cancers Symposium, 2011. PMID: None.
Carthon B, Tahir S, Araujo J, Wen S, Gallick G, Logothetis C, Thompson TC. Serum Caveolin-1 as a biomarker of Src kinase inhibition in castration resistant prostate cancer. Innovations in Cancer Research and Prevention and Research Conference, 2010. PMID: None.
Kadmon D, Sonpavde G, Jain RK, Ayala GE, Ittmann MM, Kurosaka S, Edamura K, Tabata KI, Miles BJ, Thompson TC. GLIPR1/RTVP-1 tumor suppressor gene expressed by adenovirus vector as neoadjuvant intraprostatic injection for localized high-risk prostate cancer preceding prostatectomy. 2010 ASCO Genitourinary Cancer Symposium, San Francisco, CA, 2010. PMID: None.
Tahir SA, Kurosaka S, Tanimoto R, Goltsov A, Park SH, Thompson TC. Caveolin-1 as a biomarker of drug response and therapeutic target in association with tyrosine kinase inhibitor treatment in prostate cancer models. AACR Translational Cancer Medicine 2010, Amsterdam, The Netherlands, 2010. PMID: None.
Kadmon D, Sonpavde G, Jain RK, Ayala GE, Ittmann MM, Kurosaka S, Edamura K, Tabata KI, Miles BJ, Thompson TC. GLIPR1/RTVP-1 tumor suppressor gene expressed by adenovirus vector as neoadjuvant intraprostatic injection for localized high-risk prostate cancer preceding prostatectomy. 2010 ASCO Annual Meeting, Chicago, IL, 2010. PMID: None.
Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL. Association of Caveolin-1 and -2 Genetic Variants and Post-treatment Serum Caveolin-1 with Prostate Cancer Risk and Outcomes. 42nd Annual SER Meeting, Anaheim, California, 2009. PMID: None.
Tahir SA, Park SH, Thompson TC. Caveolin-1 regulates VEGF/VEGFR2 induced angiogenic signaling. AACR 100th Annual Meeting, Denver, Colorado, 2009. PMID: None.
Li L, Ren C, Yang G, Abdel Fattah E, Timme TL, Goltsov AA, Park SH, Thompson TC. GLIPR1 tumor suppressor activities involve suppression of specificity protein1 and its target genes c-myc. AACR 100th Annual Meeting, Denver, Colorado, 2009. PMID: None.
Sonpavde G, Frolov A, Macdonell V, Hayes TG, Mims MP, Ayala GE, Wheeler TM, Thompson TC, Ittman MM, Kadmon D. Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer followed by radical prostatectomy. 2009 ASCO Annual Meeting, Orlando, Florida, 2009. PMID: None.
Miyahara Y, Kiniwa Y, Wang HY, Pen W, Peng G, Wheeler TM, Thompson TC, R-F W. Critical role of different subsets of regulatory T cells in suppressing immune responses to prostate cancer. 15th Annual SPORE Investigator’s Workshop, Baltimore, Maryland, 2007. PMID: None.
Ayala G, Li R, Wheeler TM, Thompson TC, Rowley D. Epigenetic based nomograms in prostate cancer. 15th Annual SPORE Investigator’s Workshop, Baltimore, Marlyand, 2007. PMID: None.
Ayala G, Mims MP, Wheeler TM, Tabata KI, Edamura K, Sayeeduddin M, Ren CZ, Gee A, Brenner MB, MacDonnell V, Miles BJ, Thompson TC, Kadmon D. Biological responses following intratumoral injection of AdGLIPR1: preliminary results from a Phase I/II neoadjuvant gene therapy trial. 15th Annual SPORE Investigator’s Workshop, Baltimore, Maryland, 2007. PMID: None.
Miles BJ, Yang G, Addai J, Wheeler TM, Frolov A, Kadmon D, Thompson TC. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2007. PMID: None.
Tabata K, Watanabe M, Edamura K, Yang G, Wang J, Abdel Fattah EM, Kadmon D, Thompson TC. Macrophages transduced with an adenovial vector expressing Glipr1 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. 10th Annual American Society for Gene Therapy meeting, Seattle, Washington, 2007. PMID: None.
Brown K, Thompson TC, Ren CZ, Rahmani M, and Younes M. Decreased GLIPR1 expression in esophageal adenocarcinoma. American Gastroenterology Association, Digestive Disease Week, Washington, DC, 2007. PMID: None.
Tabata K, Watanabe M, Edamura K, Wang J, Fattah A, M, Yang G, Floryk D, Kadmon D, Thompson TC. Therapeutic activities of IL-12 gene-modified macrophages embedded in gelatin matrix hemostatic sealant (FLOSEAL) in a mouse model of residual prostate cancer. Center for Cell and Gene Therapy Conference, Galveston, Texas, 2006. PMID: None.
Tahir SA, Yang G, Goltsov A, Watanabe M, Tabata K, Thompson TC. Caveolin-1 uptake by endothelial cells promotes angiogenic activities and is associated with prostate cancer progression. 4th Annual Cancer Center Symposium, Houston, Texas, 2006. PMID: None.
Goltsov AA, Ren CZ, Yang G, Wang J, Li L, Timme TL, Thompson TC. Expression and functional analysis of PERP in mouse and human prostate cancer. 4th Annual Cancer Center Symposium, Houston, Texas, 2006. PMID: None.
Kadmon D, Tabata K, Watanabe M, Naruishi K, Satoh T, Tian WT, Wang HY, Abdel Fattah M, Yang G, Thompson TC. Gene-modified macrophage therapy for recurrent prostate cancer. 14th Annual SPORE Investigator’s Meeting, Baltimore, Maryland, 2006. PMID: None.
Tabata K, Watanabe M, Satoh T, Tian WT, Wang HY, Abdel Fattah M, Yang G, Floryk D, Kadmon D, Thompson TC. Therapeutic activities of IL-12 gene-modified macrophages embedded in gelatin matrix hemostatic sealant (FloSeal) in a mouse model of residual prostate cancer. American Society of Gene Therapy 9th Annual Meeting, Baltimore, Maryland, 2006. PMID: None.
Tabata KI, Watanabe M, Naruishi K, Satoh T, Tian WT, Wang HY, E-M A, Yang G, Thompson TC, Kadmon D. Therapeutic activities of IL-12 gene-modified macrophages embedded in florseal in a mouse model of residual prostate cancer. American Urological Association meeting, Atlanta, Georgia, 2006. PMID: None.
Tahir SA, Yang G, Goltsov A, Watanabe M, Tabata K, and Thompson TC. Caveolin-1 uptake by endothelial cells promotes angiogenic activities and is associated with prostate cancer progression. American Association for Cancer Research, 97th Annual Meeting, Washington DC, 2006. PMID: None.
Goltsov A, Ren CZ, Yang G, Wang J, Li L, Timme TL, and Thompson TC. . Expression and functional analysis of PERP in mouse and human prostate cancer. American Association for Cancer Research, 97th Annual Meeting, Washington DC, 2006. PMID: None.
Thompson TC, Li L, Ren C, Ren CZ, E-M A, Goltsov A, Yang G, Wang J, Troung LD, Ittmann M, Wheeler TM, Ayala G, Kadmon D. Identification, characterization and functional analysis of RTVP-1/GLIPR-like genes – a novel p53 target gene cluster with tumor suppressor functions. 2006 Prostate Cancer Inter-SPORE Meeting, Houston, Texas, 2006. PMID: None.
Tabata KI, Watanabe M, Naruishi K, Satoh T, Tian WT, Wang HY, E-M A, Yang G, Thompson TC, Kadmon D. Therapeutic activities of IL-12 gene-modified macrophages embedded in florseal in a mouse model of residual prostate cancer. 2006 Prostate Cancer Inter-SPORE Meeting, Houston, Texas, 2006. PMID: None.
Tabata K, Watanabe M, Naruishi K, Satoh T, Tian WT, Wang H, Abdel Fattah EM, Yang G, Kadmon K, Thompson TC. Therapeutic activities of IL-12 gene-modified macrophages embedded in Floseal in a mouse model of residual prostate cancer. 2005 Center for Cell and Gene Therapy Conference, Galveston, Texas, 2005. PMID: None.
Thompson TC, Kadmon D, Li L, Ren CZ, Ren CH, Tahir S, Ayala G, Wheeler TM, Mims MP, Hayes T, Lynch GR. Development of RTVP-1 protein therapy for prostate cancer. 1st Place Award, 3rd Annual Cancer Center Symposium, Houston, TX, 2005. PMID: None.
Kadmon D, Tahir S, Li L, Ayala G, Wheeler TM, Frolov A, Thompson TC. The role of secreted caveolin-1 in prostate cancer progression. 12th Annual Prostate Cancer Foundation Scientific Retreat, Pheonix, Arizona, 2005. PMID: None.
Kadmon D, Tahir S, Li L, Ayala G, Wheeler TM, Frolov A, Thompson TC. The role of secreted caveolin-1 in prostate cancer progression. 13th Annual SPORE Investigators Workshop, Washington, DC, 2005. PMID: None.
Thompson TC, Kadmon D, Li L, Ren CZ, Ren C, Tahir S, Ayala G, Wheeler TM, Mims MP, Hayes T, Lynch GR. Development of RTVP-1 protein therapy for prostate cancer. 13th Annual SPORE Investigators Workshop, Washington, DC, 2005. PMID: None.
Wang HY, Abdelfattah M, Tahir SA, Yang G, Goltsov A, Tian WT, Ren CZ, Ren C, Timme TL, Thompson TC. RTVP-1 protein stimulates markers of maturation in mouse and human dendritic cells. American Society for Gene Therapy, St. Louis, Missouri, 2005. PMID: None.
Fujita T, Timme TL, Naruishi K, Kusaka N, Zhu JX, Yang G, Goltsov A, Ren C, Ren CZ, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy and radiotherapy in a preclinical model of metastatic prostate cancer. American Society for Gene Therapy, St. Louis, Missouri, 2005. PMID: None.
Fujita F, Timme TL, Naruishi K, Kusaka N, Zhu JX, Yang G, Goltsov A, Ren C, Ren CZ, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral-mediated interleukin 12 gene therapy and radiotherapy in a preclinical model of metastatic prostate cancer. American Urological Association Meeting, San Antonio, Texas, 2005. PMID: None.
Fujita F, Teh BS, Timme TL, Mai WY, Satoh T, Kusaka N, Naruishi K, Abdel Fattah E, Aguilar-Cordova E, Butler EB, Thompson TC. Sustained long-term immune responses following combination in situ gene therapy, radiotherapy and hormonal therapy for prostate cancer. American Urological Association meeting, San Antonio, Texas, 2005. PMID: None.
Koh M, Sanabria G, Ittmann M, Thompson TC, Leach F. F-Box gene expression as potential biomarkers for targeted therapy in prostate cancer. Inter-Prostate SPORE meeting, Houston, Texas, 2005. PMID: None.
Kadmon D, Tahir SA, Li L, Ayala G, Wheeler TM, Frolov A, Thompson TC. The role of secreted caveolin-1 in prostate cancer progression. Inter-Prostate SPORE Meeting, Houston, Texas, 2005. PMID: None.
Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Ji X, Brenner MK, Kadmon D, Thompson TC. IL-12 gene modified bone marrow stem cell therapy in a mouse model of metastatic prostate cancer. Prostate Cancer Foundation 11th Annual Scientific Retreat, Lake Tahoe, Nevada, 2004. PMID: None.
Fujita T, Timme TL, Naruishi K, Kusaka N, Zhu J, Yang G, Goltsov A, Vlachaki M, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy and radiotherapy in a preclinical model of metastatic prostate cancer. 2nd Annual Cancer Center Symposium, Houston, Texas, 2004. PMID: None.
Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Ji X, Brenner M, Kadmon D, Thompson TC. IL-12 gene modified bone marrow stem cell therapy in a mouse model of metastatic prostate cancer. 2nd Annual Cancer Center Symposium, Houston, Texas, 2004. PMID: None.
Ayala G, Li R, Frolov A, Ittman M, Dai H, Mohammed S, Scardino P, Thompson TC, Wheeler TM, Etzioni R. Increasing the predictive ability of clinico-pathologic markers for prostate cancer using biomarkers derived from high-throughput tissue microarray studies in a large retrospective cohort: A stratification strategy #125. 12th SPORE Investigators' Workshop, Baltimore, Maryland, 2004. PMID: None.
Teh BS, Amato RJ, Fujita T, Timme TL, Miles BJ, Ayala G, Wheeler TM, Kadmon D, Butler EB, Thompson TC. Combination adenoviral vector-mediated interleukin 12 gene therapy plus radiotherapy for prostate cancer #182. 12th SPORE Investigators' Workshop, Baltimore, Maryland, 2004. PMID: None.
Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Ji X, W-H T, Brenner MK, Kadmon D, Thompson TC. IL-12-transduced bone marrow cells home to bone and generate anti-metastatic activities in a mouse prostate cancer model #183. 12th SPORE Investigators' Workshop, Baltimore, Maryland, 2004. PMID: None.
Wang HY, Yang G, Timme TL, Fujita T, Naruishi K, Ji X, Brenner M, Kadmon D, Thompson TC. IL-12 transduced bone marrow cells home to bone and generate anti-metastatic activities in a mouse prostate cancer model. 7th Annual American Society of Gene Therapy meeting, Minneapolis, Minnesota, 2004. PMID: None.
Lai HH, Boone TB, Yang G, Smith CP, Kiss S, Thompson TC, Somogyi GT. Loss of caveolin-1 expression is associated with bladder hypocontraction and disruption of muscarinic cholinergic activity of the bladder via pre- and post-junctional mechanisms. American Urological Association Annual Meeting, San Francisco, California, 2004. PMID: None.
Satoh T, Teh BS, Timme TL, W-Y M, Vlachaki MT, Kusaka N, Fujita T, E-M A, Gdor Y, Kadmon D, Butler EB, and Thompson TC. Enhanced systemic T-cell responses following combination in situ gene therapy + radiotherapy or hormonal therapy for prostate cancer. American Urological Association Annual Meeting, San Francisco, California, 2004. PMID: None.
Kadmon D, Tahir SA, Timme TL, Li L, E-M A, Frolov A, Ayala G, Wheeler TM, Thompson TC. Serum caveolin-1 as a biomarker for prostate cancer. InterProstate SPORE Meeting, Chicago, Illinois, 2004. PMID: None.
Teh BS, Ayala G, Wheeler T, Miles B, Kadmon D, Amato R, Butler EB, Timme TL, Thompson TC. Combination immuno-gene therapy and irradiation for prostate cancer: achieving maximal tumor control through anti-tumor immunity. InterProstate SPORE Meeting, Chicago, Illinois, 2004. PMID: None.
Fujita T, Vlachaki MT, Zhu X, Satoh T, Naruishi K, Kusaka N, Timme TL, Teh BS, Butler EB, Thompson TC. Enhanced therapeutic effect of adenoviral vector-mediated RTVP-1 gene therapy in combination with irradiation for prostate cancer. 1st Annual Cancer Center Retreat & Symposium, Houston, Texas, 2003. PMID: None.
Naruishi K, Fujita T, Kusaka N, Goltsov AA, Ji X, Men T, Timme TL, Thompson TC. Adenoviral vector-mediated mRTVP-1 gene modified cell-based vaccination for prostate cancer. 1st Annual Cancer Center Retreat & Symposium, Houston, Texas, 2003. PMID: None.
Teh BS, Ayala G, Aguilar L, Mai WY, Valchaki M, Caillouet J, Davis M, Wheeler T, Miles B, Kadmon D, Woo SY, Carpenter LS, Lu HH, Thompson TC, Aguilar-Cordova E, Butler EB. Phase I/II trial evaluating combined radiotherapy and in-situ gene-therapy with or without hormonal therapy in the treatment of prostate cancer — a report on PSA response and biopsy data. 1st Annual Cancer Center Retreat & Symposium, Houston, Texas, 2003. PMID: None.
Li L, C-H R, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. 1st Annual Cancer Center Retreat & Symposium, Houston, Texas, 2003. PMID: None.
Wang H, Yang G, Satoh T, Kusaka N, Ji X, Timme TL, Fujita T, Men T, Brenner MK, Kadmon D, Thompson TC. Antimetastatic effects of IL-12 gene-modified bone marrow cells in a mouse model of metastatic prostate cancer. 1st Annual Cancer Center Retreat & Symposium, Houston, Texas, 2003. PMID: None.
Kadmon D, Amato RJ, Thompson TC, Miles. Development of RTVP-1 immuno-gene therapy for prostate cancer. 11th SPORE Investigators’ Workshop, Baltimore, Maryland, 2003. PMID: None.
Timme TL, Salahaldin TA, Abd-El-Fatah EA, Frolov A, Richardson B, Ayala G, Wheeler TM, Thompson TC. Serum caveolin-1 as a biomarker for prostate cancer. 11th SPORE Investigators’ Workshop, Baltimore, Maryland, 2003. PMID: None.
Ayala GA, Dai H, Frolov A, Li R, Wheeler T, Ittmann M, Thompson TC, Rowley D. Paracrine interactions between prostate cancer and nerves leads to neural hyperplasia in the prostate. 11th SPORE Investigators’ Workshop, Baltimore, Maryland, 2003. PMID: None.
Tahir SA, Ren C, Timme TL, Gdor Y, Frolov A, Hoogeveen R, Morrisett JD, Ayala G, Wheeler TM, Thompson TC. Serum caveolin-1 discriminate between BPH and prostate cancer and is a prognostic marker for prostate cancer progression. American Association for Cancer Research, Washington, DC, 2003. PMID: None.
Wang H, Yang G, Satoh T, Kusaka N, Ji X, Timme TL, Fujita T, Men T, Thompson TC. Antimetastatic effects of IL-12 gene-modified bone marrow cells in a mouse model of metastatic prostate cancer. American Society of Gene Therapy Annual Meeting, Boston, Massachusetts, 2003. PMID: None.
Satoh T, Teh BS, Timme TL, W-Y M, Vlachaki MT, Kusaka N, Fujita T, Abd-El-Fatah EA, Gdor Y, Kadmon D, Butler EB, Thompson TC. Enhanced systemic T-cell responses following combination in situ gene therapy + radiotherapy or hormonal therapy for prostate cancer. American Society of Gene Therapy Annual Meeting, Boston, Massachusetts, 2003. PMID: None.
Ayala G, Li R, Yang G, Wheeler TM, Spitler J, Frolov A, Thompson TC, Harper W. High levels of P-AKT in prostate cancer and normal tissues are independent predictors of biochemical recurrence. American Urological Association Annual Meeting, Chicago, Illinois, 2003. PMID: None.
Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, Goltsov A, Park SH, Men T, Kusaka N, Tian W, Ren C, Wang H, Kadmon D, Cai WW, Chinault AC, Boone TB Bradley A, Thompson TC. Targeted inactivation of caveolin-1 impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. American Urological Association Annual Meeting, Chicago, Illinois, 2003. PMID: None.
Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J, Ren C, Kusaka N, Mouraviev VB, Thompson TC. Adenoviral vector-mediated in situ gene therapy for prostate cancer: mRTVP-1 suppresses tumor growth and metastasis through pro-apoptotic and immunostimulatory activities. American Urological Association Annual Meeting, Chicago, Illinois, 2003. PMID: None.
Lai HH, Kiss S, Smith CP, Thompson TC, Boone TB, Somogyi GT. Cystometric abnormalities of caveolin-1 knockout mice: an animal model of urinary calculi formation. Society for Urodynamics and Female Urology / Specialty Society Meeting at American Urological Association Annual Meeting, Chicago, Illinois, 2003. PMID: None.
Saika T, Kusaka N, Satoh T, Mouraviev V, Kumon H, Timme TL, Thompson TC. Adoptive transfer of splenocytes from mice treated in situ with ADIL-12 results in suppression of tumor growth and metastasis and increased survival in a model for residual tumor after neo-adjuvant in-situ gene therapy for prostate cancer. American Urological Association Annual Meeting, Chicago, Illinois, 2003. PMID: None.
Wheeler TM, Li R, Yang G, Frolov A, Thompson TC, Harper W, Ayala G. GSK expression predicts biochemical recurrence in human prostate cancer after prostatectomy. American Urological Association Annual Meeting, Chicago, Illinois, 2003. PMID: None.
Satoh T, Vlachaki MT, Zhu X, Kusaka N, Saika T, Timme TL, Yang G, Mouraviev VB, Wang J, Teh B, Butler B, and Thompson TC. Enhanced therapeutic effect of mRTVP-1 gene therapy in combination with irradiation for prostate cancer. American Society of Gene Therapy 5th Annual Meeting, Boston, Massachusetts, 2002. PMID: None.
Saika T, Kusaka N, Satoh T, Mouraview VB, Kumon H, Timme TL, and Thompson TC. Adoptive transfer of splenocytes from mice treated in situ with AdlL-12 results in suppression of tumor growth and metastasis and increased survival in a model for risidual tumor after neo-adjuvant in situ gene therapy for prostate cancer. American Society of Gene Therapy 5th Annual Meeting, Boston, Massachusetts, 2002. PMID: None.
Ayala GE, Dai H, Wheeler T, Ali N, Thompson TC, and Ittmann M. Perineural antiapopototic mechanisms – the cancer loop. American Urological Association 97th Annual Meeting, Orlando, Florida, 2002. PMID: None.
Satoh T, H-M L, Pramudji CK, Timme TL, Shalev M, Godor Y, W-Y M, Teh B, Vlachaki MT, Saika T, Kusaka N, Ayala G, Wheeler TM, Butler EB, Miles BJ, Kadmon D, and Thompson TC. Systemic T-cell activation following in situ gene therapy in prostate cancer patients. American Urological Association 97th Annual Meeting, Orlando, Florida, 2002. PMID: None.
Ayala GE, Wheeler T, Tuxhorn J, Frolov A, Wheeler M, Spitler J, Thompson TC, and Rowley D. Quantitation of intratumoral reactive stroma as a predictor of biochemical free recurrence in prostate cancer (PCA). American Urological Association 97th Annual Meeting, Orlando, Florida, 2002. PMID: None.
Satoh T, Saika T, Ebara S, Kusaka N, Yang G, Wang J, Mouraviev V, Cao G, Timme TL, and Thompson TC. Macrophages transduced with adenoviral vectors to express IL-12 suppress tumor growth and metastasis in pre-clinical models of prostate cancer. American Urological Association 97th Annual Meeting, Orlando, Florida, 2002. PMID: None.
Saika T, Kusaka N, Satoh T, Mouraviev VB, Yang G, Timme TL, and Thompson TC. Sub-cutaneous injection of bone marrow derived dendritic cells engineered to produce interleukin-12 induces anti-tumor activities in an orthotopic mouse prostate cancer model. American Urological Association 97th Annual Meeting, Orlando, Florida, 2002. PMID: None.
Harper W, Yang G, Wheeler T, Frolov A, Thompson TC, and Ayala GE. Elevated Skp2 protein expression in human prostate cancer is associated with reduced recurrence-free survival. American Urological Association 97th Annual Meeting, Orlando, Florida, 2002. PMID: None.

Book Chapters

Thompson TC, Tahir S, Li L, Watanabe M, Naruishi K, Yang G, Tabata K, Kurosaka S, Edamura K, Tanimoto R, Corn P, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression. In: Caveolins in Cancer Pathogenesis, Prevention and Therapy. None. Springer, 1-15, 2012.
Thompson, Timme, Hall, Stapleton. Perspectives on the Molecular Biology of Prostate Cancer. In: Comprehensive Textbook of Genitourinary Oncology. None. Williams & Wilkins, None, 1996.
Thompson TC, Kadmon D, Arnall MF, Flanagan WF, Egawa S, Scardino PT, Park S, Merz VW. Evidence for the involvement of genetic differences and mesenchymal factors in the progression of oncogene-induced prostate cancer in reconstituted mouse prostate. In: Molecular and Cellular Biology of Prostate Cancer. None. Plenum Press, 1991.
Satoh T, Timme TL, Gdor Y, Miles BJ, Amato RJ, Kadmon D, and Thompson TC. Immunogene therapy for metastatic prostate cancer. In: Cancer Metastatsis: Biology and Treatment. None. None.

Letters to the Editor

Geng, C, Thompson, T. DNA Damage Response Inhibitor and Anti-PD-L1 Therapy for Prostate Cancer. Engineering 12: 12-15, 2022.

Less

Grant & Contract Support

Title:	Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Patient-Derived Models of Prostate Cancer for Personalized Medicine
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Cancer Center Support (CORE) Grant - Prostate Cancer Program
Funding Source:	NIH/NCI
Role:	Co-Program Leader

Title:	ATR Inhibitor and PSMA-TTC-Based Combination Therapy Approaches in Prostate Cancer Model Systems
Funding Source:	Bayer Healthcare Pharmaceuticals Inc
Role:	PI

Title:	Non-Invasive Biomarkers for Patient Selection of Combination PARP Inhibition and Androgen Receptor Signaling Inhibition in Hormone-Sensitive Prostate Cancer
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Prostate Cancer-Associated SPOP Mutations Modulate Innate Immune Response and Immune Checkpoint Therapy
Funding Source:	NIH/NCI
Role:	PI

Title:	Contribution of Cancer Cell Intrinsic and Extrinsic Androgen Receptor Signaling to Prostate Cancer and Influence of the Western Diet
Funding Source:	NIH/NCI
Role:	Collaborator

Title:	Lipidomics-based Biomarkers for Risk of Progression in Early Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Flagship Project 3: DNA Damage Response (DDR) Targeted Therapies for Aggressive Variant Prostate Cancer (AVPC)
Funding Source:	MD Anderson Moon Shot Program
Role:	Investigator

Title:	MD Anderson Cancer Center Prostate Cancer SPORE and Administrative Supplement
Funding Source:	NIH/NCI
Role:	Multiple Principal Investigator; Basic Co-leader, Project 3 (1.20 CM); Director, Administrative Core (1.20 CM); Director, DRP (0.30 CM)

Title:	MD Anderson Cancer Center Prostate Cancer SPORE – Administrative Core
Funding Source:	NIH/NCI
Role:	Core Director

Title:	Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer
Funding Source:	NIH/Ohio State University
Role:	Subcontract PI

Title:	MD Anderson Cancer Center Prostate Cancer SPORE – Developmental Research Program
Funding Source:	NIH/NCI
Role:	Director

Title:	MD Anderson Cancer Center Prostate Cancer SPORE – Project 3: Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC
Funding Source:	NIH/NCI
Role:	Basic Co-Leader

Title:	Prostate Cancer Moon Shot: Integrated Plan for Reducing Mortality of Advanced Prostate Cancer
Funding Source:	MD Anderson Moon Shot Program
Role:	Co-PI

Title:	MD Anderson Cancer Center Prostate Cancer SPORE Core A: Administrative
Funding Source:	MD Anderson - Internal Funding
Role:	Director, Administrative Core

Title:	MD Anderson Cancer Center Prostate Cancer Spore - Project 3: Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC
Funding Source:	MD Anderson - Internal Funding
Role:	Co-Leader

Title:	Development of Predictive Biomarker for Therapeutic Response of Aggressive Variant Prostate Cancer
Funding Source:	Anthony Cox MS Prostate
Role:	PI

Title:	Investigational New Drug Production Core Facility at Scott & White Cancer Research Institute
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Sub-Contractor PI

Title:	Androgenic Regulation of White Adipose Tissue-Prostate Cancer Interactions
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI

Title:	M. D. Anderson Cancer Center Prostate SPORE - Core A: Administrative Core
Funding Source:	NIH/NCI
Role:	Co-Director, Administrative Core

Title:	M.D. Anderson Cancer Center Prostate SPORE (PP-1) GLIPR1- ΔTM Protein Therapy for Prostate Cancer
Funding Source:	NIH/NCI
Role:	Co-Leader, Project 1

Title:	Cancer Center Support (CORE) Grant, Prostate Cancer Program
Funding Source:	NIH/NCI
Role:	Co-Leader, GU Cancers Program

Title:	Mechanisms of Progression in Oncogene-Induced Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Prostate Cancer Specialized Program of Research Excellence (SPORE)
Funding Source:	NIH/NCI
Role:	PI

Title:	Mechanisms of Metastasis in Experimental Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Role of Caveolin-1 in Prostate Cancer Angiogenesis
Funding Source:	Department of Defense (DOD)
Role:	PI

Title:	Transgenic Mouse Models to Study Androgen Regulation of Prostate Cancer
Funding Source:	Department of Defense (DOD)
Role:	PI

Title:	Career Development
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Research Development
Funding Source:	NIH/NCI
Role:	PI

Title:	In Situ Gene Therapy for Prostate Cancer: Development of Systemic Anti-Tumor Immunity
Funding Source:	Department of Defense (DOD)
Role:	PI

Title:	Caveolin-1 as a Bio-Marker for Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Development of RTVP-1 Gene Therapy for Prostate Cancer
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Administrative Core
Funding Source:	NIH/NCI
Role:	PI

Title:	Mechanisms of Progression in Oncogene-Induced Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Mechanisms of Metastasis in Oncogene-Induced Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Immunomodulatory Prostate Cancer Gene Therapy: Antimetastatic and Adjuvant Approaches
Funding Source:	Association for the Cure of Cancer of the Prostate (CaP CURE)
Role:	PI

Title:	Molecular Pathways in Hormone-Refractory Prostate Cancer
Funding Source:	Department of Defense (DOD)
Role:	PI

Title:	Specialized Program of Research Excellence (SPORE) in Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Development of Gene Based Markers and Therapy for Prostate Cancer Progression
Funding Source:	Association for the Cure of Cancer of the Prostate (CaP CURE)
Role:	Co-I

Title:	Prostate Cancer Gene Therapy: Antimetastatic Immunomodulatory Approaches
Funding Source:	Association for the Cure of Cancer of the Prostate (CaP CURE)
Role:	PI

Title:	In Vivo Gene Therapy for Prostate Cancer
Funding Source:	Association for the Cure of Cancer of the Prostate (CaP CURE)
Role:	PI

Title:	Neoadjuvant Pre-radical Prostatectomy Gene Therapy in Patients With Poor Prognostic Indicators
Funding Source:	Association for the Cure of Cancer of the Prostate (CaP CURE)
Role:	Co-I

Title:	Prostate Cancer Gene Therapy: Anti-Metastatic Approaches
Funding Source:	Association for the Cure of Cancer of the Prostate (CaP CURE)
Role:	PI

Title:	Molecular Markers for Prostate Cancer Progression
Funding Source:	Association for the Cure of Cancer of the Prostate (CaP CURE)
Role:	Co-I

Title:	Mechanisms of Progression in Oncogene Induced Prostate Cancer
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Conference on Breast and Prostate Cancer: Basic Mechanisms
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Biological Therapy for Prostate Cancer
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Gene Therapy for Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Markers of Progression and Metastasis
Funding Source:	NIH/NCI
Role:	PI

Title:	Mechanisms of Metastasis in Oncogene-Induced Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Apoptosis as a Predictor for the Progression of Human Prostate Cancer: Multivariant Analysis for Prognosis
Funding Source:	ONCOR, Inc
Role:	PI

Title:	Immunomodulatory Prostate Cancer Gene Therapy: Antimetastatic and Adjuvant Approaches
Funding Source:	Association for the Cure of Cancer of the Prostate (CaP CURE)
Role:	PI

Title:	Gene Therapy for Prostate Cance
Funding Source:	NIH/NCI
Role:	PI

Title:	Combination Biological Therapy for Metastatic Prostate Cancer in a Transgenic/Mouse Prostate Reconstitution Model
Funding Source:	Association for the Cure of Cancer of the Prostate (CaP CURE)
Role:	PI

Title:	Mechanisms of Recurrent Prostate Cancer
Funding Source:	Veterans Administration
Role:	Co-I

Title:	Effect of Growth Modulators on Prostate Cancer – Chemoprevention Feasibility Study
Funding Source:	NIH/NCI
Role:	PI

Title:	DNA Ploidy and Molecular Markers of Prostate Cancer
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Complementation of p53 Mutation in Oncogene-Induced Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Transforming Growth Factor β Regulation of T-Cell Response in Prostate Carcinogenesis
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Development of Methodology for the Detection of Early Stage Prostate Cancer
Funding Source:	Lamar Fleming Fund
Role:	PI

Title:	Mechanisms of Progression in Oncogene-Induced Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Mesenchymal Growth Factor Activities in a Mouse BPH Model
Funding Source:	NIH/NCI
Role:	PI

Title:	Biochemical and Immunochemical Evaluation of Benign and Malignant Prostate Neoplasia Growth Processes
Funding Source:	Eli Lilly and Co
Role:	PI

Title:	Role of ras Oncogenes in Prostatic Neoplasms
Funding Source:	Veterans Administration
Role:	Co-I

Title:	Mechanisms of Progression in Oncogene-Induced Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Androgen Receptor in Progression of Prostatic Carcinoma
Funding Source:	USPHS
Role:	PI

Title:	SPOP Mutation-Driven STING Signaling Promotes Tumor Microenvironment Reprogramming and Therapeutic Vulnerabilities in Prostate Cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	Therapeutic reprogramming of the tumor and tumor microenvironment in metastatic, treatment-emergent neuroendocrine prostate cancer
Funding Source:	NIH/NCI
Role:	PI

Title:	MD Anderson Cancer Center Prostate Cancer SPORE
Funding Source:	NIH/NCI
Role:	Co-PI

Title:	Targeting Treatment-emergent, PD-L1-driven Prostate Cancer Neuroendocrine Lineage Plasticity
Funding Source:	NIH/NCI
Role:	PI

CV information above last modified December 02, 2024

Timothy C. Thompson, Ph.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Timothy C. Thompson, Ph.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer